bgslider
  • 1 in 15,000.
    That’s approximately how many people worldwide who have Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damage. Wilson Disease is universally fatal if left undiagnosed and untreated.

    However, a rare disease is only rare until you or someone you know is affected. At Wilson Therapeutics, we are focused on improving the lives of patients with this serious disease through development of new treatment options and support for increased awareness and education.

  • LEARN FROM THE COMMUNITY

    Watch a video about Wilson Disease featuring patients, physicians and others affected by this rare genetic disease.

    Living with Wilson Disease

     
  • NEWS

    • Wilson Therapeutics appoints Hans Schikan to its Board of Directors.

      Read more >>
    • View the eposter about our ongoing Phase 2 Study in Wilson Disease from the EASL 50th International Liver Congress 2015.

      Read more >>
    • Wilson Therapeutics Announces Support of the BIG WOW to Raise Awareness of 
      Wilson’s Disease.

      Read more >>
    • Watch the latest video from the Big Wow, a new initiative aimed at raising awareness of Wilson Disease.

      Read more >>
    • Wilson Therapeutics to present as a “next wave” company during BioEquity 2015
      Conference in Vienna on May 19th.

      Read more >>
    • YaleNews: Yale researchers test drug for Wilson Disease in clinical trial.

      Read more >>
    • Wilson Therapeutics announces presentation of WTX101-201 Phase 2 study at the EASL 50th International Liver Congress 2015.

      Read more >>
    • Wilson Therapeutics announces successful filing of U.S. IND to advance WTX101 development program for Wilson Disease.

      Read more >>
    • Wilson Therapeutics secures $40 million private financing to advance late stage development program for Wilson`s Disease.

      Read more >>
    • Wilson Therapeutics announces start of Phase 2 study to evaluate the efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients.

      Read more >>
     
  • PHASE 2 STUDY OPEN FOR PATIENT RECRUITMENT

    Learn more about our Phase 2 study with newly diagnosed Wilson Disease patients.

    Read more >>

     

     
© Copyright 2014 Wilson Therapeutics. All rights reserved.